DRUG · COUNSELLING NOTES
Agalsidase Beta
Fabrazyme
Updated
New prescription
indication: _____. IV infusion q2 weeks; report chills, fever; warned on allergies; serious/common AEs: infusion reactions, anaphylaxis, headache; non-pharm: physiotherapy, activity pacing.
Refill prescription
refilled, adherence discussed, no SEs were reported
Dose change
Dose change discussed. new dose reviewed; IV infusion q2 weeks; report chills, fever; warned on allergies; serious/common AEs: infusion reactions, anaphylaxis, headache; non-pharm: physiotherapy, activity pacing.